Trials / Completed
CompletedNCT04969211
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
An Open-Label, Two-Period, Randomized, Single Oral Dose, Crossover Study to Evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a single center, two-period, randomized study to evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VHX-896 and iloperidone | oral tablet |
| DRUG | Iloperidone and VHX-896 | oral tablet |
Timeline
- Start date
- 2021-06-30
- Primary completion
- 2021-10-13
- Completion
- 2021-10-13
- First posted
- 2021-07-20
- Last updated
- 2022-07-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04969211. Inclusion in this directory is not an endorsement.